Wisconsin is currently home to 1261 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Milwaukee, Madison, Green Bay and Marshfield. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients
NCT03945162
Recruiting
This is a phase II, open-label, single-arm, multi-center Study conducted in Canada and the United States. Patients with NMIBC CIS (with or without resected papillary disease (Ta, T1)) that are considered Bacillus Calmette-Guerin ("BCG")-Unresponsive or who are intolerant to BCG therapy. BCG-Unresponsive is at least one of the following: At least five of six doses of an initial induction course plus at least two of three doses of maintenance therapy; or, at least five of six doses of an initial i... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/27/2023
Locations: Site 02-011 - University of Wisconsin Health University Hospital, Madison, Wisconsin
Conditions: Non-Muscle Invasive Bladder Cancer ("NMIBC") Unresponsive/Intolerant to BCG
Register for Updates
KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment
NCT03662126
Recruiting
This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the treatment of patients with myelofibrosis (MF) who no longer benefit from treatment with a JAK inhibitor. Inhibition of MDM2 is a novel mechanism of action in MF. This study will be conducted in 2 phases. Phase 2 will determine the KRT-232 recommended dose and dosing schedule; Phase 3 will test KRT-232 vs Best Available Therapy (BAT). Patients in the Phase 3 part of the study will be randomized 2:1 to receive ei... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/26/2023
Locations: Medical College of Wisconsin - Froedtert Hospital, Milwaukee, Wisconsin
Conditions: Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Post-Essential Thrombocythemia MF (Post-ET-MF)
Register for Updates
PTGS1 Genetic Variation and Increased Risk for Persistent Pulmonary Hypertension of the Newborn
NCT00710177
Recruiting
The purpose of this study is to determine if normally occurring variations in a specific gene called PTGS-1 are associated with an increased risk of narrowing of the ductus arteriosus from exposure to over-the-counter pain medicines (NSAIDs).
Gender:
ALL
Ages:
12 months and below
Trial Updated:
03/14/2023
Locations: Children's Wisconsin, Milwaukee, Wisconsin
Conditions: Persistent Pulmonary Hypertension of the Newborn
Register for Updates
Genetic Variants and Susceptibility to Diseases of Prematurity in Very Low Birth-Weight Infants
NCT00710112
Recruiting
The purpose of this study is to determine if sequence variations in genes involved in the development and function of vulnerable organs increases susceptibility to chronic lung disease (CLD) and other diseases affecting premature infants, such as necrotizing enterocolitis (NEC), sepsis, patent ductus arteriosus (PDA) and intraventricular hemorrhage (IVH). The study will also determine whether measurement of certain biomarkers in serum will identify infants who will develop these complications of... Read More
Gender:
ALL
Ages:
All
Trial Updated:
03/14/2023
Locations: Children's Wisconsin, Milwaukee, Wisconsin
Conditions: Chronic Lung Disease
Register for Updates
Systematic Efficacy Replication Study of Conjoint Behavioral Consultation in Elementary Schools
NCT05466214
Recruiting
The purpose of this project is to conduct an impact evaluation of the Conjoint Behavioral Consulting (CBC) intervention under real-world conditions as an IES Efficacy Replication trial. CBC is a family-school partnership intervention proven efficacious for children with serious emotional and behavior problems. The investigation will conduct a systematic efficacy replication of CBC to identify important process and context variables in need of attention prior to a CBC effectiveness study. School-... Read More
Gender:
ALL
Ages:
Between 4 years and 10 years
Trial Updated:
02/07/2023
Locations: Madison Metropolitan School District, Madison, Wisconsin
Conditions: Emotional Disturbances
Register for Updates
Life After Sport: Prior Injury and Sedentary Behavior as Mechanisms of Later Poor Health
NCT05344001
Recruiting
Competitive sport increases risk for musculoskeletal injury (e.g., traumatic knee injury) and may position former athletes for early onset of chronic diseases, chronic pain, poor health-related quality of life, and disability. Quantifying function in former athletes with and without a prior injury and non-athlete controls is critical to understanding long-term health trajectories in athletes and informing potential interventional studies. One modifiable factor that may be associated with long-te... Read More
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
08/22/2022
Locations: Marquette University, Milwaukee, Wisconsin
Conditions: Aging, Athletic Injuries, Physical Inactivity, Knee Injuries and Disorders
Register for Updates
Clinical Registry Investigating Bardet-Biedl Syndrome
NCT02329210
Recruiting
Bardet-Biedl Syndrome (BBS) is a rare genetic disorder associated with a vast array of symptoms. The features of BBS are highly variable, even between siblings, making long-term follow-up and centralization of information vital to better understanding this complex disease and designing effective treatments. Marshfield Clinic has developed the Clinical Registry Investigating Bardet-Biedl Syndrome (CRIBBS) to gather comprehensive health information from patients diagnosed with BBS in a single rep... Read More
Gender:
ALL
Ages:
All
Trial Updated:
07/18/2022
Locations: Marshfield Clinic Research Foundation, Marshfield, Wisconsin
Conditions: Bardet-Biedl Syndrome
Register for Updates
Renal Metabolism in Salt-sensitive Human Blood Pressure
NCT05369416
Recruiting
Salt sensitive hypertension is a significant health problem worldwide and a primary modifiable risk factor for renal, cardiovascular, and cerebrovascular diseases. Yet, the underlying mechanisms remain poorly understood. The proposed study determines how renal oxygenation and substrate metabolism differs between individuals with and without salt sensitivity, with the ultimate goal of identifying mechanisms, diagnostic criteria, and treatment strategies for salt sensitive hypertension.
Gender:
ALL
Ages:
Between 30 years and 65 years
Trial Updated:
05/23/2022
Locations: Medical College of Wisconsin /Froedtert Hospital, Milwaukee, Wisconsin
Conditions: Hypertension
Register for Updates
KRT-232 and TKI Study in Chronic Myeloid Leukemia
NCT04835584
Recruiting
This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the treatment of patients with Ph+ Chronic Myeloid Leukemia (CML) who have relapsed or are refractory or intolerant to a Tyrosine Kinase Inhibitor (TKI). This study is a global, open label Phase 1b/2 to determine the efficacy and safety of KRT-232 in patients with chronic phase CML (CML-CP) and accelerated phase (CML-AP) who have failed TKI treatments.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/04/2022
Locations: Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Chronic Myeloid Leukemia
Register for Updates
Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL
NCT05211856
Recruiting
The purpose of this study is to evaluate the efficacy and safety of acalabrutinib in combination with venetoclax and acalabrutinib in combination with venetoclax with and without obinutuzumab compared to chemoimmunotherapy in subjects with previously untreated CLL.
Gender:
All
Ages:
Between 18 years and 130 years
Trial Updated:
01/14/2022
Locations: Research Site, Madison, Wisconsin
Conditions: Chronic Lymphocytic Leukemia
Register for Updates
Blinatumomab After TCR Alpha Beta/CD19 Depleted HCT
NCT04746209
Recruiting
This trial will assess the feasibility of alpha/beta T-cell and B-cell depleted allogeneic hematopoietic cell transplantation (HCT) followed by blinatumomab therapy for high-risk B cell acute lymphoblastic leukemia (ALL) as a means of reducing rates of subsequent relapse and improving survival, while also minimizing treatment-related morbidity/ mortality and late effects. The conditioning regimens will be dependent on the patient's minimal residual disease (MRD) status prior to HCT using high th... Read More
Gender:
ALL
Ages:
25 years and below
Trial Updated:
09/12/2021
Locations: Children's Hospital of Wisconsin, Milwaukee, Wisconsin
Conditions: B-cell Acute Lymphoblastic Leukemia, B-cell Childhood Acute Lymphoblastic Leukemia, B-Cell ALL, Childhood
Register for Updates
iCareDx PSS-1 Point-of-Care (POC) Assay for Detection of COVID-19
NCT04937595
Recruiting
Purpose of this clinical investigation is to establish the performance of the iCareDx PSS-1 RT PCR POC Testing Platform which is used to detect COVID-19 in symptomatic patients using the patients saliva. The study focuses on obtaining a minimum of 30 positive and 30 negative test for this study. Results will serve to establish the assay's performance. Symptomatic patients who are being tested for COVID-19 will be enrolled and consented into this study. If the patient consents, 2 saliva specimens... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/22/2021
Locations: Froedtert Health WAC, Wauwatosa, Wisconsin
Conditions: Covid19
Register for Updates